Clinical Trial Update: A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) [Phase 2]

View source ↗

Summary

Clinical trial update for Raludotatug Deruxtecan (R-DXd) in gastrointestinal cancers; the Phase 2 study MK-5909-005 is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Raludotatug Deruxtecan (R-DXd) (Raludotatug deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastrointestinal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING